Stockscreener 앱 받기
92.01
0.39%
0.36
시간 외 거래:
92.01
Medtronic Plc 주식(MDT)의 최신 뉴스
Medtronic receives Type 2 label expansion for MiniMed 780G in Europe - MedTech Dive
What analysts say about Medtronic plc stockExplosive capital appreciation - Autocar Professional
Medtronic plc (NYSE:MDT) is largely controlled by institutional shareholders who own 87% of the company - simplywall.st
What drives Medtronic plc stock priceDynamic profit opportunities - Autocar Professional
Medtronic plc Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
Is Medtronic plc a good long term investmentJaw-dropping returns - jammulinksnews.com
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know - Nasdaq
Medtronic gets EU nod for MiniMed 780G System - MSN
Medtronic’s (MDT) Role in Medical Devices: A Unique Fit for Halal Portfolios - MSN
Medtronic (MDT): A Shariah-Compliant Powerhouse in the Evolving Medical Device Sector - AInvest
Medtronic MiniMed 780G wins CE mark for type 2 diabetes, young children - MassDevice
Court Nixes Jury Award Over Medtronic's Heart Valve Infringement ClaimMedtronic (NYSE:MDT) - Benzinga
Medtronic gets EU nod for MiniMed 780G System (MDT:NYSE) - Seeking Alpha
Medtronic (MDT) Expands MiniMed 780G System Indications with Eur - GuruFocus
Medtronic expands MiniMed 780G system indications across Europe - Investing.com Australia
Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes - Medtronic
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever - The Motley Fool
Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict - MassDevice
Fed. Circ. Frees Medtronic From $125M Patent Judgment - Law360
Medtronic wins appeal to avoid $106.5M patent verdict (MDT:NYSE) - Seeking Alpha
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict - Reuters
Breaking Barriers: Medtronic and Zverev Unite - Il Messaggero
Medtronic’s SWOT analysis: renal denervation, diabetes spin-off to drive stock - Investing.com
Medtronic enrolls first patient in study for Onyx liquid embolic system - MassDevice
Analyst Expectations For Medtronic's Future - Benzinga
Got Their Backs: How Medtronic Brings Spine Surgeries to Kids - Yahoo Finance
Medtronic gets CE mark for robot-driven vessel-sealing device - MedTech Dive
Baird Adjusts Medtronic Price Target to $94 From $92, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Medtronic Price Target to $107 From $98, Maintains Overweight Rating - MarketScreener
Medtronic : first in the U.S. to offer 400 cm 0.018” peripheral guidewire for transradial access - MarketScreener
Medtronic, Renal Denervation, and the Power of Persistence - Medical Device and Diagnostic industry
Medtronic (MDT) Price Target Raised by Morgan Stanley | MDT Stoc - GuruFocus
Medtronic shaping future of surgery, secures CE Mark for LigaSure™ technology on Hugo™ robotic-assisted surgery system - Medtronic
Medtronic (MDT) Experiences Increased Bearish Options Activity | MDT Stock News - GuruFocus
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
Medtronic Stock Is Climbing Friday: What's Going On?Medtronic (NYSE:MDT) - Benzinga
Medtronic (MDT) Stock Insights and Investment Tools | MDT Stock News - GuruFocus
Medtronic (MDT) Gains from CMS Proposal on Renal Denervation Coverage | MDT Stock News - GuruFocus
Medtronic Says Centers for Medicare & Medicaid Services Proposes National Coverage for Blood Pressure Treatment Device - MarketScreener
Unusual Options Activity Noticed for Medtronic (MDT) | MDT Stock News - GuruFocus
Medtronic (MDT) Set for Growth with Proposed Coverage for Renal Denervation | MDT Stock News - GuruFocus
Medtronic (MDT) Gains Following Medicare's Review of New Hypertension Technology | MDT Stock News - GuruFocus
William Blair reiterates Market Perform rating on Medtronic stock after CMS proposal - Investing.com
1.46%
자본화:
|
볼륨(24시간):